Essential Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Essential Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-37	Closed	-$1.16K	–	2895
2026 Q2	$1.16K	Buy	37 +12	+48%	+$354	﹤0.01%	2176
2026 Q1	$619	Buy	25 +2	+9%	+$48	﹤0.01%	2372
2025 Q4	$537	Buy	23 +7	+44%	+$156	﹤0.01%	2216
2025 Q3	$315	Sell	16 -487	-97%	-$10K	﹤0.01%	2311
2025 Q2	$10.9K	Buy	+503	New	+$11.9K	﹤0.01%	822

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's CPRX Position: Q3 2026 in Review

Essential Partners sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 37 shares — an estimated $1.16K sold.

Essential Partners first reported a position in CPRX in Q2 2025 and held it in 5 quarters. The position peaked at $10.9K in Q2 2025. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

Essential Partners reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Essential Partners sold 37 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.16K.
Essential Partners first reported a position in Catalyst Pharmaceutical in Q2 2025 and held it in 5 quarters.
Essential Partners's Catalyst Pharmaceutical position peaked at $10.9K in Q2 2025.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.